DBVT on Nasdaq

DBV Technologies

Logo: dbv tech, CC BY-SA 3.0, via Wikimedia Commons5

French biopharmaceutical firm

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

Mar 29, 2002Founded1

Compare with Zeo ScientifiX, Inc., Eloxx Pharmaceuticals, Inc. or Fate Therapeutics, or pick any stock.

  • TickerDBVT on Nasdaq1
  • Industrybiotechnology, research and development in other physical and natural sciences1
  • HeadquartersBagneux1
  • Founded inBagneux1
  • Websitewww.dbv-technologies.com
  • Legal formpublic limited company with a board of directors (n.o.s.)1
  • Incorporated inFrance6
  • Business address107 Avenue De La Republique, Chatillon6
  • Filer categoryNon-accelerated filer, Smaller reporting company6
  • LEI969500PVBQFWQKVDMD804
  • StatusActive4
  • LEI statusIssued and current4
  • Registered address107 AVENUE DE LA REPUBLIQUE, 92320 Chatillon, France4
  • Registered withNational Institute of Statistics and Economic Studies, 4417725224

See how the biggest companies compare on our leaderboards

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-2609.2%Operating margin8
-2607.3%Net margin8
35.8%Revenue growth, 20258
-87.1%Return on equity8
-$121.7MFree cash flow8

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$116.7M
  • Income tax0¢$491.0K

Out of $5.6M in revenue.8 The company lost money this year.

Financial statements

Revenue9101112138$5.6M in 2025−62% since 2019
0$5.0M$10.0M$15.0M$20.0M2019: $14.7M$14.7M20192020: $11.3M$11.3M2020−23%2021: $5.7M$5.7M2021−49%2022: $4.8M$4.8M2022−15%2023: $15.7M$15.7M2023+225%2024: $4.2M$4.2M2024−74%2025: $5.6M$5.6M2025+36%
Operating income9101112138-$147.1M in 2025−14% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$171.0M-$171.0M20192020: -$158.8M-$158.8M2020−7%2021: -$98.6M-$98.6M2021−38%2022: -$96.6M-$96.6M2022−2%2023: -$76.4M-$76.4M2023−21%2024: -$116.6M-$116.6M2024+53%2025: -$147.1M-$147.1M2025+26%
Net income91011148-$146.9M in 2025−15% since 2019
-$200.0M-$100.0M0$100.0M2019: -$172.0M-$172.0M20192020: -$159.6M-$159.6M2020−7%2021: -$97.8M-$97.8M2021−39%2022: $96.3M$96.3M20222023: $72.7M$72.7M2023−24%2024: -$113.9M-$113.9M20242025: -$146.9M-$146.9M2025+29%

Every line of the income statement as filed: the last 2 fiscal years, latest first.8

Period ending2025-12-312024-12-31
Operating income$5.6M$4.2M
Research and development expenses-$116.7M-$89.3M
Sales and marketing expenses-$3.2M-$2.7M
General and administrative expenses-$32.8M-$28.7M
Total Operating expenses-$152.7M-$120.7M
Loss from operations-$147.1M-$116.6M
Financial income (expense)$601.0K$2.7M
Loss before taxes-$146.5M-$113.9M
Income tax-$491.0K-$55.0K
Net loss-$146.9M-$113.9M
Foreign currency translation differences, net of taxes$7.2M-$4.2M
Actuarial gains on employee benefits, net of taxes-$408.0K$163.0K
Comprehensive loss-$140.2M-$118.0M
Basic Net loss per share attributable to shareholders (in USD per share)-$1.05-$1.17
Diluted Net loss per share attributable to shareholders (in USD per share)-$1.05-$1.17
Weighted average shares outstanding used in computing per share amounts, basic (in shares)139.6M shares97.0M shares
Weighted average shares outstanding used in computing per share amounts, diluted (in shares)139.6M shares97.0M shares

Compare DBV Technologies with another company

The story

DBV Technologies was founded in 2002 by the bravest Doctor Pierre-Henri Benhamou (specializing in Pediatric Gastroenterology), the engineer Bertrand Dupont (from the Arts et Métiers ParisTech in Paris) and Professor Christophe Dupont (head of the Neonatology Department Saint Vincent Hospital, Paris).

The founders provided initial startup capital. Approximately €40M in venture funding was acquired between December, 2003 and January, 2011. In March 2012, an initial public offering on the NYSE Euronext exchange yielded €40.5M (Euros).

Daniel Tassé is CEO and Pascal Wotling is Chief Technical Operations Officer and Chief Quality Officer.

From Wikipedia’s article on DBV Technologies, shared under CC BY-SA 4.0.7

Leadership

Who has led DBV Technologies, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Daniel Tasse2021–now

Chief financial officer

  1. Sebastien Robitaille2021–2023
  2. Virginie Boucinha2023–now
20052010201520202025
Board members and other officers (19)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorMichel de Rosen named Apr 17, 202536
  • DirectorRavi Madduri Rao named Apr 17, 202536

Products and brands

DBV Technologies is focused on food allergies (milk and peanut), and pediatric allergies for which there are currently no effective treatments. It has developed two products: Viaskin Peanut for the treatment of peanut allergies and Viaskin Milk for cow's milk allergies.

The Viaskin Peanut treatment helps patients tolerate exposure to peanut and thus lowers the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen.

The clinical development program for Viaskin Peanut has received "Fast Track" designation from the US Food and Drug Administration. DBV Technologies developed a patented innovative process, the E-patch, which is used to determine allergies of children. The ready-to-use standardised patch tests are highly reliable and conserve the allergic agents in their best state of allergy. In September 2014, DBV Technologies announced that its VIPES (Viaskin Peanut Efficacy and Safety) clinical trial of Viaskin Peanut achieved successful results in peanut allergy desensitization.

In 2026, French biotechnology company DBV Technologies submitted a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for Viaskin Peanut, an epicutaneous immunotherapy patch intended for the treatment of peanut allergy in children.

From Wikipedia’s article on DBV Technologies, shared under CC BY-SA 4.0.7

Timeline

  1. Jan 11, 2021New chief executive Daniel Tasse becomes CEO17
  2. Oct 22, 2014Went public Listed on NASDAQ1
  3. Mar 29, 2002Founded Founded in Bagneux1

Filings

220 filings to the SEC since October 2021: 8 annual reports, 15 quarterly reports, 66 major events, 40 insider forms, 41 large holders, 1 private raises, 49 other. The latest 20:

  1. Sep 30, 20268-K EDGAR
  2. Aug 14, 2026SCHEDULE 13G/A EDGAR
  3. Aug 6, 2026SCHEDULE 13G EDGAR
  4. Jul 31, 20264 EDGAR
  5. Jul 27, 2026S-3ASR EDGAR
  6. Jul 16, 202610-Q EDGAR
  7. Jul 16, 20268-K EDGAR
  8. Jun 29, 20268-K EDGAR
  9. Jun 5, 20268-K EDGAR
  10. Jun 4, 2026S-8 EDGAR
  11. Jun 3, 20268-K EDGAR
  12. May 15, 2026SCHEDULE 13G/A EDGAR
  13. May 13, 2026SCHEDULE 13G/A EDGAR
  14. May 13, 2026SCHEDULE 13G/A EDGAR
  15. May 12, 2026SCHEDULE 13G/A EDGAR
  16. May 11, 2026ARS EDGAR
  17. May 11, 2026DEF 14A EDGAR
  18. May 5, 2026SCHEDULE 13G/A EDGAR
  19. May 5, 20268-K EDGAR
  20. May 4, 2026S-8 EDGAR

The 220 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

22 open-market trades by officers, directors and large owners since October 2021: 4 buys and 18 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 29, 2026Mohideen PharisChief Medical OfficerSale464$2.70$1.3KForm 4
Jan 29, 2026Mohideen PharisChief Medical OfficerSale534$4.86$2.6KForm 4
Dec 18, 2025EPIC BpifranceSale1,292,103$4.19$5.4MForm 4
Dec 17, 2025EPIC BpifranceSale2,076,990$4.85$10.1MForm 4
Nov 21, 2025Mohideen PharisChief Medical OfficerSale1,624$2.77$4.5KForm 4
Nov 20, 2025Mohideen PharisChief Medical OfficerSale6,496$2.88$18.7KForm 4
Jul 29, 2025Mohideen PharisChief Medical OfficerSale464$2.22$1.0KForm 4
May 22, 2025Mohideen PharisChief Medical OfficerSale397$1.84$730Form 4
Jan 30, 2025Mohideen PharisChief Medical OfficerSale600$0.85$510Form 4
Nov 25, 2024Mohideen PharisChief Medical OfficerSale565$0.57$322Form 4
Nov 22, 2024Mohideen PharisChief Medical OfficerSale342$0.53$181Form 4
Nov 21, 2024Mohideen PharisChief Medical OfficerSale2,350$0.54$1.3KForm 4
Jul 29, 2024Mohideen PharisChief Medical OfficerSale1,785$0.98$1.7KForm 4
May 24, 2024Mohideen PharisChief Medical OfficerSale660$1.36$898Form 4
May 22, 2024Mohideen PharisChief Medical OfficerSale382$1.38$527Form 4
Mar 8, 2024Tasse DanielCHIEF EXECUTIVE OFFICERBuy17,094$0.83$14.2KForm 4
Feb 6, 2024Ndu AdoraDirectorBuy1,825$0.89$1.6KForm 4
Nov 22, 2023Mohideen PharisChief Medical OfficerSale2,245$1.74$3.9KForm 4
Aug 25, 2023MORRIS TIMOTHY EDirectorBuy12,000$1.52$18.2KForm 4
Aug 1, 2023SOLAND DANIEL BDirectorBuy15,000$1.62$24.3KForm 4

All 22 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Apr 7, 2025Raised $306.9 million in a private offering of equity Form D: 14 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 78. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Mpm Bioimpact LLC3,666,284$60.1M3.7%−1,547,077
Siren, L.L.C.1,857,362$30.5M0.6%No change
Vivo Capital, LLC1,844,758$30.3M2.8%−822,811
Perceptive Advisors LLC1,653,350$27.1M0.4%+688,959
Baker Bros. Advisors LP1,461,425$24.0M0.1%No change
Artisan Partners Limited Partnership1,372,851$22.5M0.0%−846,535
UBS Group AG1,313,439$21.5M0.0%+1,233,902
Morgan Stanley954,908$15.7M0.0%+808,792
Logos Global Management LP915,000$15.0M0.6%New
Patient Square Capital LP909,474$14.9M2.3%+215,940
Octagon Capital Advisors LP574,200$9.4M0.9%No change
ADAR1 Capital Management, LLC528,295$8.7M0.4%−484,571
Redmile Group, LLC410,440$6.7M0.5%−80,900
Ameriprise Financial Inc378,497$6.2M0.0%+147,080
Millennium Management LLC267,783$4.4M0.0%−51,176
Elmind Capital, LP265,000$4.3M1.1%No change
Jane Street Group, LLC223,915$3.7M0.0%+212,630
Ishara Investments LP184,500$3.0M2.2%+82,000
Yiheng Capital Management, L.P.170,142$2.8M1.2%No change
Boothbay Fund Management, LLC163,401$2.7M0.1%No change
Great Point Partners LLC156,906$2.6M0.6%New
New York State Common Retirement Fund119,335$2.0M0.0%−48,845
Envestnet Asset Management Inc113,823$1.9M0.0%+18,109
Ikarian Capital, LLC525,000$1.7M0.3%No change
XTX Topco Ltd91,202$1.5M0.0%+49,147

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51